Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 30 Jan 2022 |